Shijiazhuang Yiling Pharmaceutical (SHE:002603) through unit Wanyang Hengshui Pharmaceutical, received a certificate of suitability from the European Union's pharmaceutical regulator for the active pharmaceutical ingredient, Letrozole, according to a Thursday filing on the Shenzhen bourse.
The API, which inhibits estrogen synthesis, is used in the treatment of breast cancer.
The Chinese pharmaceutical company's shares rose 1% at the close.